6275 Nancy Ridge Drive, Suite 110
About Organovo, Inc.
Organovo (NASDAQ MKT: ONVO) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications.
The Company is collaborating with a variety of pharmaceutical, academic and other partners to develop human biological tissues in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed safer, faster and at lower cost. In addition to numerous scientific publications, our technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and other outlets.
Organovo is changing the shape of life sciences, medical research and practice. Check out our current openings to see how you can “Change the Shape of Your Future at Organovo”.
106 articles with Organovo, Inc.
The collaboration will focus on expanding the use of 3D bioprinted stem cell-based therapeutic tissues. The goal is to develop treatments for end-stage renal disease.
A recent survey by the Pew Research Center found that 57 percent of Americans surveyed thought it was appropriate to use genetically engineered animals to grow organs for human transplants.
An article published earlier this summer in the Journal of Dental Research suggests that “bioengineered tooth buds” are a “superior alternative tooth replacement therapy.” In the article “Bioengineered Tooth Buds Exhibit Features of Natural Tooth Buds,” the authors report that artificial implants...
Organovo Holdings, Inc. announced the grant of inducement awards on August 14, 2018 to Dr. Steven G. Hughes, its new chief medical officer.
Organovo Reports Fiscal First-Quarter 2019 Results; Company Outlines and Expands Key Clinical Development Goals
Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019
Organovo Holdings, Inc. announced that Steven G. Hughes has been named Chief Medical Officer. Dr. Hughes is an industry veteran who brings significant experience directing clinical development and medical affairs teams at leading biopharma companies.
There has been recent coverage of 3D bioprinting and how it has the potential to create a brave new world of printed organs to be used in biopharma research and maybe someday to even be used in organ transplants.
Organovo today reported financial results for the fiscal third quarter of 2018 and updated its full-year fiscal 2018 outlook.
In advance of the call on February 8, 2018, Organovo will issue its fiscal third-quarter 2018 earnings press release, which will be available at http://www.organovo.com.
Organovo Receives Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin Deficiency
Organovo is now qualified to receive significant benefits throughout its orphan drug development program including more frequent FDA interactions, protocol assistance, and tax credits for clinical research costs.
Organovo Announces Fiscal Second-Quarter 2018 Results; Company Shifts Commercial Focus to Higher-Value Disease Modeling Opportunities and Updates Full-Year Fiscal 2018 Outlook
The Company is shifting the focus of its commercial and platform development efforts toward higher-demand and higher-value disease modeling services, and is deprioritizing routine toxicology research services.
Organovo and Viscient Biosciences Collaborate to Develop Custom Research Platform for Studying Liver Disease
The partnership is expected to expand upon Organovo’s current service portfolio for compound screening in disease models.
Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Inborn Errors of Metabolism at The Liver Meeting 2017 (AASLD)
This data will be presented by Vaidehi Joshi, Scientist I, Therapeutics, at Organovo.
In advance of the call on November 9, 2017, Organovo will issue its fiscal second-quarter 2018 earnings press release.
Organovo Announces Preliminary Fiscal Second-Quarter Total Revenue; Company Restructures To Improve Operational Efficiency
Organovo Sponsors Pioneering Research With Amgen And Medikine In Critical Areas Of Liver And Kidney Disease
Organovo And University of California, San Diego (UCSD) Receive $1.7 Million Grant From NIH To Study Liver Disease
Organovo Announces Fiscal Fourth-Quarter And Full-Year 2017 Results; Company Issues Full-Year Fiscal 2018 Outlook
Organovo Presents New Preclinical Data On 3D Bioprinted Human Liver Tissues At World Advanced Therapies And Regenerative Medicine Congress